Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07241468RecruitingEarly Phase 1
CAR-T cell therapy for immune kidney disease
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
ShanghaiAges 18–70 - NCT07249073RecruitingEarly Phase 1
Dual-target CAR-T for relapsed/refractory myeloma
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07249528Recruiting
Using voice recordings to monitor side effects during CAR T-cell therapy
This study tests if daily voice recordings on a smartphone can help detect side effects early in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. You will make short voice recordings twice a day and have daily neurological checks.
Basking Ridge, New JerseyAges 18 years+ - NCT07247734RecruitingPhase 2
Colchicine for insulin sensitivity in type 1 diabetes
This trial tests whether a daily oral medication called colchicine can improve how your body responds to insulin. It is for people with type 1 diabetes who have ongoing low-level inflammation and are already using a continuous glucose monitor.
Gentofte MunicipalityAges 18–80 - NCT07246213Recruiting
Childhood cancer survivor research study
This study looks back at the medical records of children and young adults diagnosed with cancer in the last 15 years. It helps researchers understand more about cancer in young people.
YerevanAges birth–21 years - NCT07241117RecruitingPhase 4
Community health center asthma support study
This study tests a new way to help manage asthma in community health centers. If you have moderate to severe asthma, you may be able to join and get extra support to improve your asthma control.
St Louis, MissouriAges 12 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT05954507Recruiting
PET/MRI scan to assess heart risk in sarcoidosis
This study checks whether a special heart scan called PET/MRI can predict how sarcoidosis may affect your heart. It may help doctors better estimate heart risk and plan follow-up based on scan findings.
CréteilAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT06794008RecruitingPhase 2
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
Beijing, Beijing MunicipalityAges 18–65 - NCT06897605RecruitingPhase 2
Dapagliflozin for anemia in kidney disease
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Al MansurahAges 18 years+ - NCT05530096Recruiting
Genetic test to find minimal residual myeloma in remission
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
Montreal, QuebecAges 18 years+ - NCT06068582Recruiting
Keep your memory sharp and stay at work with MS
This study tests a program of physical and mental exercises designed to slow down memory and thinking problems in people with multiple sclerosis, and help them stay employed longer.
AmsterdamAges 18–67 - NCT07233720Recruiting
Zanubrutinib plus rituximab for first-line marginal zone lymphoma
This trial tests a combination of two targeted drugs (zanubrutinib and rituximab) as a first treatment for marginal zone lymphoma. The goal is to see how well this drug pair works for people who have not received any prior cancer therapy.
Zhengzhou, HenanAges Any age - NCT07234773RecruitingPhase 1
Study of a new injectable drug for rheumatoid arthritis
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
BayswaterAges 18–75 - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07230483RecruitingPhase 2
Long-term safety of CM512 for atopic dermatitis
This study is for people who have already completed a previous study of CM512 for atopic dermatitis. It will check if the medicine is safe and works well over a longer period.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07234825Recruiting
Trial of dairy-free diet with liquid nutrition for eosinophilic esophagitis
This study tests whether a dairy-free diet combined with a special liquid nutrition drink (called Kate Farms) can help children and young adults with eosinophilic esophagitis (a condition where certain white blood cells build up in the esophagus and cause trouble swallowing, pain, or vomiting). The goal is to see if this combination can reduce symptoms and improve quality of life.
Seattle, WashingtonAges 1–21 - NCT07230353RecruitingPhase 1
Plamotamab for moderate to severe rheumatoid arthritis
This trial tests a new treatment called plamotamab for people with moderate to severe rheumatoid arthritis (RA) who have not had enough relief from current treatments. The goal is to see if it is safe and to help control RA symptoms.
TbilisiAges 18 years+ - NCT07236099RecruitingPhase 2
Study of ICP-332 for prurigo nodularis
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
Birmingham, AlabamaAges 18–75 - NCT07237659RecruitingPhase 1
Testing safety of NTR-1011 in lupus and rheumatoid arthritis
This trial is testing a new medicine called NTR-1011 to see if it is safe and tolerable for people with lupus or rheumatoid arthritis. If you have active lupus or RA and are on a stable treatment plan, you may be able to join.
Apple Valley, CaliforniaAges 18–75 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.